A detailed history of Versant Capital Management, Inc transactions in Exact Sciences Corp stock. As of the latest transaction made, Versant Capital Management, Inc holds 32 shares of EXAS stock, worth $1,839. This represents 0.0% of its overall portfolio holdings.

Number of Shares
32
Previous 38 15.79%
Holding current value
$1,839
Previous $1,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 07, 2024

SELL
$42.43 - $70.83 $254 - $424
-6 Reduced 15.79%
32 $2,000
Q2 2024

Jul 05, 2024

BUY
$41.33 - $74.26 $1,570 - $2,821
38 New
38 $1,000
Q4 2023

Jan 08, 2024

SELL
$59.06 - $75.72 $354 - $454
-6 Reduced 30.0%
14 $1,000
Q2 2023

Jul 10, 2023

BUY
$62.68 - $95.05 $1,253 - $1,901
20 New
20 $1,000
Q1 2020

Apr 17, 2020

SELL
$37.9 - $104.44 $151 - $417
-4 Closed
0 $0
Q4 2019

Jan 28, 2020

BUY
$77.66 - $99.74 $310 - $398
4 New
4 $0

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $10.2B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Versant Capital Management, Inc Portfolio

Follow Versant Capital Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Versant Capital Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Versant Capital Management, Inc with notifications on news.